LAG3 and head and neck squamous cell carcinoma: Based on the high levels of CTLA-4 and Lag3 expressed on CD8 T cells in these tumors, we pursued combination immunotherapy targeting these two additional inhibitory receptors to further improve the effectiveness of α-PD-1 therapy against orthotopic HNSCC.